PMID- 26191249
OWN - NLM
STAT- MEDLINE
DCOM- 20160524
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 5
DP  - 2015
TI  - Effects of preventative application of metformin on bile acid metabolism in high 
      fat-fed/streptozotocin-diabetic rats.
PG  - 5450-6
AB  - OBJECTIVE: This study was designed to investigate the effects of metformin on 
      bile acid in type 2 diabetes mellitus (T2DM). METHODS: In this study, we 
      constructed a model of T2DM by a combination of high-fat diet (HFD) and low dose 
      of streptozotocin (STZ) intraperitoneal injection. Blood samples by tail vein and 
      eye angular vein were withdrawn before (time 0) and 30, 60, and 120 minutes after 
      administration of glucose before STZ injection and once a week after diabetes 
      induction, and were analyzed to evaluate the level of the fasting blood glucose 
      and fasting insulin using glucometer. Triglyceride, low density lipoprotein 
      cholesterin, high density lipoprotein cholesterin were detected by automatic 
      biochemical analyzers. Total cholesterol and total bile acid (TBA) were analyzed 
      using ELISA kits. RESULTS: Before STZ injection, the TBA level in HFD group was 
      significantly higher relative to that in standard diet (SD) group and there was a 
      moderate reduction of the TBA level in early intervention (EI) group 6 week after 
      metformin administration comparing with that in HFD group but was still higher 
      than that of SD group. However, after STZ injection, the TBA level was 
      significantly higher in DM rats relative to that in normal control (NC) rats and 
      the TBA level in late intervention (LI) (19.92 mumol/L) and EI rats (42.97 mumol/L) 
      with metformin administration was significantly higher comparing with that in DM 
      rats. CONCLUSION: The effects of metformin in plasma glucose and lipid metabolism 
      might be associated with bile acid metabolism.
FAU - Ding, Lin
AU  - Ding L
AD  - Medical School of Shandong University Jinan, 250013, Shandong Province, People's 
      Republic of China ; Jinan Central Hospital Affiliated to Shandong University 
      Jinan 250013, Shandong Province, People's Republic of China.
FAU - Qu, Zhiping
AU  - Qu Z
AD  - Medical School of Shandong University Jinan, 250013, Shandong Province, People's 
      Republic of China ; Jinan Central Hospital Affiliated to Shandong University 
      Jinan 250013, Shandong Province, People's Republic of China.
FAU - Chi, Jinfeng
AU  - Chi J
AD  - Jinan Central Hospital Affiliated to Shandong University Jinan 250013, Shandong 
      Province, People's Republic of China.
FAU - Shi, Rui
AU  - Shi R
AD  - Jinan Central Hospital Affiliated to Shandong University Jinan 250013, Shandong 
      Province, People's Republic of China ; Department of Medicine, Taishan Medical 
      University Shandong Province, People's Republic of China.
FAU - Wang, Lulu
AU  - Wang L
AD  - Jinan Central Hospital Affiliated to Shandong University Jinan 250013, Shandong 
      Province, People's Republic of China.
FAU - Hou, Lulu
AU  - Hou L
AD  - Jinan Central Hospital Affiliated to Shandong University Jinan 250013, Shandong 
      Province, People's Republic of China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Medical School of Shandong University Jinan, 250013, Shandong Province, People's 
      Republic of China ; Jinan Central Hospital Affiliated to Shandong University 
      Jinan 250013, Shandong Province, People's Republic of China.
FAU - Pang, Shuguang
AU  - Pang S
AD  - Medical School of Shandong University Jinan, 250013, Shandong Province, People's 
      Republic of China ; Jinan Central Hospital Affiliated to Shandong University 
      Jinan 250013, Shandong Province, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150501
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Bile Acids and Salts/*metabolism
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Experimental/*metabolism
MH  - *Diet, High-Fat
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin/blood
MH  - Insulin Resistance/*physiology
MH  - Lipid Metabolism/*drug effects
MH  - Lipids/blood
MH  - Male
MH  - Metformin/*pharmacology
MH  - Rats
MH  - Rats, Wistar
PMC - PMC4503120
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - metformin
OT  - streptozotocin
OT  - total bile acid
EDAT- 2015/07/21 06:00
MHDA- 2016/05/25 06:00
PMCR- 2015/05/01
CRDT- 2015/07/21 06:00
PHST- 2015/01/18 00:00 [received]
PHST- 2015/03/20 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/05/25 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 May 1;8(5):5450-6. eCollection 2015.